Ocular Therapeutix, Inc. Net Change in Cash
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | $18.5M | ($6,349.0K) | $19.9M | ($6,609.0K) | $2,152.0K | $8,602.0K | $17.5M | ($4,475.0K) | $173.6M | ($63.9M) | ($61.9M) | $93.5M | $196.1M |
Ocular Therapeutix, Inc. (OCUL) Net Change in Cash comparison analysis
General
LTM Net Change in Cash
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
OCUL key stats
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 (100.0%) | 0.8 0.0% | 1.8 126.7% | 1.9 7.8% | 1.9 1.9% | 2.0 3.5% | 4.2 112.4% | 17.4 311.7% | 43.5 150.1% | 51.5 18.3% | 58.4 13.5% | 63.7 9.0% |
| Cost of Goods Sold (COGS) | 0.0 | 10.5 | 0.1 | 0.3 | 0.4 | 0.5 | 0.5 | 2.3 | 2.1 | 4.4 | 4.5 | 5.3 | 5.6 |
% margin | 0.0 30.0% | (10.5) 0.0% | 0.7 88.2% | 1.4 81.8% | 1.4 76.5% | 1.5 76.2% | 1.5 76.6% | 1.9 45.0% | 15.3 88.0% | 39.1 89.9% | 47.0 91.2% | 53.2 91.0% | 58.1 91.2% |
| Operating Expenses | 13.7 | 12.9 | 27.8 | 39.6 | 44.8 | 63.4 | 60.6 | 87.7 | 78.2 | 117.2 | 125.6 | 135.5 | 229.9 |
| Research & Development Expenses (R&D) | 11.5 | 10.5 | 18.9 | 26.6 | 27.1 | 30.9 | 36.9 | 41.1 | 28.7 | 50.1 | 53.5 | 61.1 | 127.6 |
| Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 8.9 | 13.0 | 17.7 | 32.5 | 23.7 | 46.6 | 49.5 | 67.1 | 72.1 | 74.5 | 102.2 |
% margin | (13.7) (136,710.0%) | (12.9) 0.0% | (27.1) (3,509.6%) | (38.2) (2,182.7%) | (43.3) (2,296.0%) | (61.9) (3,220.1%) | (59.1) (2,970.8%) | (85.8) (2,029.9%) | (62.8) (361.1%) | (78.0) (179.3%) | (78.7) (152.7%) | (82.4) (141.0%) | (171.8) (269.6%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 | 0.4 | 0.9 | 1.2 | 0.2 | 0.0 | 0.8 | 4.0 | 20.3 |
| Interest Expense | 0.4 | 0.4 | 1.1 | 1.7 | 1.7 | 1.9 | 1.7 | 6.1 | 6.8 | 6.7 | 7.0 | 11.3 | 13.6 |
| Pre-tax Income | (14.1) | (13.3) | (28.6) | (39.7) | (44.7) | (63.4) | (60.0) | (86.4) | (155.6) | (6.6) | (71.0) | (80.7) | (193.5) |
% effective tax rate | 0.3 (2.3%) | 0.5 (3.4%) | 0.1 (0.5%) | 1.0 (2.5%) | 0.8 (1.8%) | 0.3 (0.4%) | (2.3) 3.8% | 3.6 (4.1%) | 4.0 (2.6%) | 4.3 (64.9%) | (7.6) 10.7% | 0.0 0.0% | 0.0 0.0% |
% margin | (14.1) (140,930.0%) | (13.3) 0.0% | (28.6) (3,710.9%) | (39.7) (2,271.3%) | (44.7) (2,369.0%) | (63.4) (3,296.2%) | (57.7) (2,899.1%) | (89.9) (2,127.6%) | (159.6) (917.3%) | (10.8) (24.8%) | (63.4) (123.2%) | (80.7) (138.1%) | (193.5) (303.7%) |
| EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.14) | (0.83) | (1.09) | (1.22) |
| Diluted EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.13) | (0.83) | (1.02) | (1.22) |
% margin | (13.3) (133,120.0%) | (12.5) 0.0% | (27.0) (3,495.1%) | (37.3) (2,129.7%) | (42.1) (2,233.3%) | (59.9) (3,113.3%) | (56.0) (2,811.7%) | (77.7) (1,839.2%) | (146.1) (839.5%) | (75.6) (173.7%) | (61.9) (120.2%) | (66.4) (113.6%) | (176.1) (276.4%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Ocular Therapeutix, Inc.'s Net Change in Cash?
As of today, Ocular Therapeutix, Inc.'s last 12-month Net Change in Cash is $197.8M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Ocular Therapeutix, Inc.'s Net Change in Cash growth rate?
Over the last year, Ocular Therapeutix, Inc.'s Net Change in Cash growth was 111.2%. The average annual Net Change in Cash growth rates for Ocular Therapeutix, Inc. have been 22.5% over the past three years, N/A over the past five years.
3) Is Ocular Therapeutix, Inc.'s Net Change in Cash growth rate Good?
Over the last year, Ocular Therapeutix, Inc.'s Net Change in Cash growth was 111.2%, which is higher than industry growth of (0.6%). It indicates that Ocular Therapeutix, Inc.'s Net Change in Cash growth is Good.